Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy

Massimo Breccia; Alessandra Iurlo; Fabrizio Pane; Anna Rita Scortechini; Antonella Russo Rossi; Marco Santoro; Marco Cerrano; Francesca Lunghi; Alessandro Maggi; Nicola Di Renzo; Valeria Sargentini; Alfonso Piciocchi; Claudia Tringali; Alessandra Malato

doi:10.3324/haematol.2026.300586

Letters to the Editor

Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy

Massimo Breccia
Alessandra Iurlo
Fabrizio Pane
Anna Rita Scortechini
Antonella Russo Rossi
Marco Santoro
Marco Cerrano
Francesca Lunghi
Alessandro Maggi
Nicola Di Renzo
Valeria Sargentini
Alfonso Piciocchi
Claudia Tringali
Alessandra Malato

Division of Haematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome

Haematology Division, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan

A.O.U. Federico II, UOC Ematologia, Napoli

Division of Haematology, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona

Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari

Haematology Unit, AOU Policlinico Paolo Giaccone, University of Palermo, Palermo

A.O.U. Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette, SC Ematologia, Torino

Haematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute, Milan

Division of Hematology and Bone Marrow Transplantation, Hospital “S.G. Moscati”, Taranto

Department of Haematology and Stem Cell Transplant, Presidio Ospedaliero Vito Fazzi, Lecce

GIMEMA Foundation, Rome

Incyte Biosciences Italy S.R.L., Milan

Division of Haematology, Ospedali Riuniti Villa Sofia-Cervello, Palermo

Haematologica Early view May 14, 2026 https://doi.org/10.3324/haematol.2026.300586

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2026.300586

Published

2026-05-14

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

No Data Yet

No Data

PlumX

Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More